Kentaro Takayama Selected Research

Myostatin

3/2022	Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice.
1/2022	Peptide Tool-Driven Functional Elucidation of Biomolecules Related to Endocrine System and Metabolism.
1/2021	Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation.
8/2020	Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
8/2019	Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides.
1/2019	[Medicinal Chemistry Focused on Mid-sized Peptides Derived from Biomolecules].
1/2019	Design and synthesis of potent myostatin inhibitory cyclic peptides.
1/2017	Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide.
4/2016	Effect of N-Terminal Acylation on the Activity of Myostatin Inhibitory Peptides.
2/2015	Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kentaro Takayama Research Topics

Disease

5	Muscular Dystrophies (Muscular Dystrophy) 01/2021 - 04/2016
5	Neoplasms (Cancer) 08/2020 - 04/2010
5	Obesity 01/2020 - 08/2014
3	Muscular Atrophy (Muscle Atrophy) 03/2022 - 01/2015
3	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 10/2019 - 02/2015
3	Glioma (Gliomas) 01/2014 - 09/2009
2	Cachexia 08/2020 - 04/2016
2	Inborn Genetic Diseases (Disease, Hereditary) 10/2017 - 10/2014
1	Colitis 01/2022
1	Muscular Diseases (Myopathy) 01/2022
1	Phototoxic Dermatitis (Phototoxicity) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020
1	Muscle Weakness 01/2019
1	Sarcopenia 04/2016
1	Heart Failure 09/2015
1	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2015
1	Body Weight (Weight, Body) 08/2011
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 04/2010
1	Urinary Bladder Neoplasms (Bladder Cancer) 04/2010

Drug/Important Bio-Agent (IBA)

11	MyostatinIBA 03/2022 - 01/2015
9	Peptides (Polypeptides)IBA 01/2021 - 09/2009
3	neuromedin UIBA 01/2020 - 11/2016
3	Nonsense Codon (Nonsense Mutation)IBA 10/2019 - 06/2015
3	Pharmaceutical PreparationsIBA 01/2019 - 08/2014
2	Proteins (Proteins, Gene)FDA Link 08/2020 - 04/2010
2	Messenger RNA (mRNA)IBA 09/2015 - 08/2011
2	Arginine (L-Arginine)FDA Link 04/2010 - 09/2009
1	Dextran SulfateIBA 01/2022
1	SolutionsIBA 01/2022
1	Silicon Dioxide (Silica)FDA LinkGeneric 01/2020
1	neuromedin U receptorIBA 01/2020
1	BoronIBA 01/2020
1	GadoliniumIBA 01/2020
1	Cell-Penetrating PeptidesIBA 01/2020
1	Amino Acids FDA Link 10/2019
1	EstersIBA 10/2017
1	pyroglutamyl-histidyl-glycineIBA 11/2016
1	ProdrugsIBA 07/2016
1	Immunoglobulin G (IgG)IBA 07/2016
1	NPI 2358IBA 07/2016
1	Immunoconjugates (Immunoconjugate)IBA 07/2016
1	FurinIBA 09/2015
1	HydrazinesIBA 06/2015
1	DystrophinIBA 06/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2015
1	negamycinIBA 06/2015
1	CaveolinsIBA 01/2015
1	polyarginineIBA 01/2014
1	Small Interfering RNA (siRNA)IBA 08/2011
1	AcidsIBA 04/2010
1	Protein SIBA 04/2010

Therapy/Procedure

2	Therapeutics 08/2011 - 04/2010
1	Boron Neutron Capture Therapy 01/2020
1	Intramuscular Injections 01/2015
1	Drug Therapy (Chemotherapy) 12/2012